pit565
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 3, 2022 (NCT05397496)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- T-cell surface antigen CD2ACTIVATOR
CD2 activator
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07029555 | Phase 1 | Jun 12, 2025 | Novartis |
| NCT06335979 | Phase 1 | Oct 9, 2024 | Novartis |
| NCT05397496 | Phase 1 | Oct 3, 2022 | Novartis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 3 | 1 | 2022 |
1 organizations
Page 1 / 1